Krogerus advises Synexa Life Sciences on its acquisition of Syrinx Bioanalytics

Krogerus advised Synexa Life Sciences B.V., a Dutch-based biomarker and bioanalytical science company backed by a leading European healthcare investor, Gilde Healthcare, on its acquisition of Syrinx Bioanalytics Oy, a bioanalytical contract research organization (CRO) based in Finland and specialising in high-quality bioanalysis for biopharma drug development programs.

The acquisition is part of Synexa's ongoing growth strategy, aimed at building the global market leader in specialist biomarker and bioanalytical services. The two companies' service offerings are very complementary, allowing the combined group to offer clients a broader range of services, deeper scientific expertise, a wider set of analytical platforms, greater capacity and an expanded geographical footprint. Syrinx is particularly strong in PK / immunogenicity bioanalysis, while Synexa's core strengths lie in its broad portfolio of specialist biomarker and bioanalytical assays, spanning DNA, RNA, protein, cell and tissue capabilities.

The Krogerus team was led by Senior Associate Antti Luhtala and he was primarily supported by Senior Advisor Lennart Simonsen and Associates Juho Lakkala and Ari Natunen. Partner Samu Lassila, Senior Associate Vilma Piipponen and Associate Sakari Kalpio advised on tax matters.